Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 15 de 15
Filtrar
1.
Neuropsychiatr Dis Treat ; 18: 1433-1440, 2022.
Artigo em Inglês | MEDLINE | ID: mdl-35859803

RESUMO

Despite many available treatments for schizophrenia, several unmet needs persist in treating individuals with this disorder, and the response rate to first-line antipsychotics remains relatively low. Clozapine has shown efficacy in treating schizophrenia patients who failed to respond to previous antipsychotics. However, side effects and the need for routine blood tests have limited its use as a first-line treatment. Cariprazine is a D2/D3 partial agonist antipsychotic with a mechanism of action that differs from other antipsychotics due to its higher affinity for D3 receptors. Several trials have demonstrated the efficacy of cariprazine on positive and negative symptoms of schizophrenia and have shown that it is a well-tolerated treatment. In this series, we present 3 cases of patients diagnosed with schizophrenia who were initially under treatment with clozapine. Despite some initial improvement, the patients showed persisting positive and negative symptoms or developed limiting side effects while in treatment with clozapine. Cariprazine treatment was titrated concurrently with clozapine tapering until its discontinuation. Significant improvement in both positive and negative symptoms was observed up to 14 months after starting cariprazine, and resolution of side effects was reported in all cases. Our case series supports cariprazine as an effective treatment for positive and negative symptoms in patients who failed to adequately respond or poorly tolerated treatment with clozapine, as well as a potential treatment in dual disorders, specifically psychotic disorders and cocaine use disorder.

2.
Biomedica ; 36(1): 121-32, 2016 Mar 03.
Artigo em Inglês | MEDLINE | ID: mdl-27622445

RESUMO

INTRODUCTION: Bacterial infections represent a serious complication of liver cirrhosis. Traditionally, Gram negative bacteria have been described as the microorganisms responsible for the majority of the infections. However, in the past few years, changes in the microbiological spectrum have been described, and multiresistant bacteria are observed more frequently.  OBJECTIVE: To assess the proportion of patients with infections caused by multiresistant bacteria admitted to our hospital, and to obtain information about their epidemiology, risk factors and clinical impact.  MATERIALS AND METHODS: We performed a retrospective evaluation of 294 cirrhotic patients admitted to our unit due to infection between June, 2011, and June, 2013.  RESULTS: We isolated 310 microorganisms from 294 patients; 109 (35.2%) were Gram positive, 167 (53.9%), Gram negative, and 34, fungi (11%). As for the microbiological agents, the most frequent was Escherichia coli (98 isolations). The infection was community-acquired in 22.9% of cases, healthcareassociated in 38.1% and nosocomial in 39%. Worse liver infections and septic shock were more frequent among patients with multiresistant isolates (p=0.05); and intrahospital mortality was also higher among them (p=0.017). Previous hospital admission, antibiotic treatment 60 days before, nosocomial or healthcare-associated acquisition and bacterial isolation in control cultures were identified as possible risk factors for the development of multiresistant infection.  DISCUSSION: The results of our study confirm that important changes have ocurred in the microbiological spectrum of bacterial infections in patients with liver cirrhosis. Multiresistant bacteria are associated with high morbidity and mortality, as well as failure of traditional antibiotic treatment. Successfull control of the infection requires an early identification of patients at risk.


Assuntos
Infecções Bacterianas/epidemiologia , Infecção Hospitalar/epidemiologia , Cirrose Hepática/epidemiologia , Adulto , Idoso , Idoso de 80 Anos ou mais , Antibacterianos/uso terapêutico , Infecções Bacterianas/microbiologia , Comorbidade , Infecção Hospitalar/microbiologia , Suscetibilidade a Doenças , Farmacorresistência Bacteriana Múltipla , Feminino , Hepatite C Crônica/epidemiologia , Mortalidade Hospitalar , Humanos , Cirrose Hepática Alcoólica/epidemiologia , Masculino , Pessoa de Meia-Idade , Micoses/epidemiologia , Estudos Retrospectivos , Espanha/epidemiologia , Centros de Atenção Terciária/estatística & dados numéricos
3.
Biomédica (Bogotá) ; 36(1): 121-132, ene.-mar. 2016. ilus, graf, tab
Artigo em Espanhol | LILACS | ID: lil-779538

RESUMO

Introducción. Las infecciones bacterianas representan una complicación grave de la cirrosis. En los últimos años se han observado cambios en el espectro microbiológico de estas infecciones, fundamentalmente, el aumento de infecciones por gérmenes multirresistentes. Objetivo. Establecer la proporción de infecciones por microorganismos multirresistentes en pacientes cirróticos ingresados en un centro de atención de Madrid, y analizar su epidemiología, factores de riesgo e impacto clínico. Materiales y métodos. Se hizo un estudio retrospectivo en el cual se evaluaron 294 pacientes hospitalizados por infección bacteriana en el Hospital General Universitario Gregorio Marañón de Madrid, entre junio de 2011 y junio de 2013. Resultados. Se aislaron 310 microorganismos de 223 pacientes; 109 (35,2 %) eran Gram positivos, 167 (53,9 %), Gram negativos, y 34 (11 %), hongos. El agente etiológico más frecuente fue Escherichia coli (98 aislamientos). Las infecciones se habían adquirido en la comunidad en 22,9 % de los casos, se asociaron con la atención de salud en 38,1 % y se adquirieron durante la estancia hospitalaria en 39 %. Los pacientes con aislamientos multirresistentes desarrollaron con más frecuencia choque séptico (p=0,05), y presentaron peor función hepática y alta mortalidad durante la estancia hospitalaria (p=0,017). El ingreso previo, el uso de antibióticos en los 60 días anteriores, la adquisición de la infección en el hospital o asociada a un ingreso reciente y el aislamiento de bacterias en los cultivos de control, se determinaron como posibles factores de riesgo para el desarrollo de la infección multirresistente. Discusión. Los resultados del estudio confirmaron que el espectro microbiológico de las infecciones bacterianas en pacientes con cirrosis ha sufrido importantes cambios. Las infecciones por gérmenes multirresistentes causan infecciones con gran morbimortalidad y el fracaso del tratamiento antibiótico habitual. Para controlarlas de forma eficaz, es imprescindible detectar precozmente a aquellos pacientes con factores de riesgo.


Introduction: Bacterial infections represent a serious complication of liver cirrhosis. Traditionally, Gram negative bacteria have been described as the microorganisms responsible for the majority of the infections. However, in the past few years, changes in the microbiological spectrum have been described, and multiresistant bacteria are observed more frequently. Objective: To assess the proportion of patients with infections caused by multiresistant bacteria admitted to our hospital, and to obtain information about their epidemiology, risk factors and clinical impact. Materials and methods: We performed a retrospective evaluation of 294 cirrhotic patients admitted to our unit due to infection between June, 2011, and June, 2013. Results: We isolated 310 microorganisms from 294 patients; 109 (35.2%) were Gram positive, 167 (53.9%), Gram negative, and 34, fungi (11%). As for the microbiological agents, the most frequent was Escherichia coli (98 isolations). The infection was community-acquired in 22.9% of cases, healthcare-associated in 38.1% and nosocomial in 39%. Worse liver infections and septic shock were more frequent among patients with multiresistant isolates (p=0.05); and intrahospital mortality was also higher among them (p=0.017). Previous hospital admission, antibiotic treatment 60 days before, nosocomial or healthcare-associated acquisition and bacterial isolation in control cultures were identified as possible risk factors for the development of multiresistant infection. Discussion: The results of our study confirm that important changes have ocurred in the microbiological spectrum of bacterial infections in patients with liver cirrhosis. Multiresistant bacteria are associated with high morbidity and mortality, as well as failure of traditional antibiotic treatment. Successfull control of the infection requires an early identification of patients at risk.


Assuntos
Adulto , Idoso , Idoso de 80 Anos ou mais , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Infecções Bacterianas/epidemiologia , Infecção Hospitalar/epidemiologia , Cirrose Hepática/epidemiologia , Espanha/epidemiologia , Infecções Bacterianas/microbiologia , Comorbidade , Infecção Hospitalar/microbiologia , Estudos Retrospectivos , Mortalidade Hospitalar , Hepatite C Crônica/epidemiologia , Farmacorresistência Bacteriana Múltipla , Suscetibilidade a Doenças , Centros de Atenção Terciária/estatística & dados numéricos , Cirrose Hepática Alcoólica/epidemiologia , Antibacterianos/uso terapêutico , Micoses/epidemiologia
4.
Emerg Infect Dis ; 19(10): 1605-11, 2013 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-24050302

RESUMO

Plasmodium vivax is a major cause of illness in areas with low transmission of malaria in Latin America, Asia, and the Horn of Africa. However, pregnancy-associated malaria remains poorly characterized in such areas. Using a hospital-based survey of women giving birth and an antenatal survey, we assessed the prevalence rates of Plasmodium spp. infections in pregnant women in Bolivia, and evaluated the consequences of malaria during pregnancy on the health of mothers and newborns. P. vivax infection was detected in 7.9% of pregnant women attending antenatal visits, and placental infection occurred in 2.8% of deliveries; these rates did not vary with parity. Forty-two percent of all P. vivax malaria episodes were symptomatic. P. vivax-infected pregnant women were frequently anemic (6.5%) and delivered babies of reduced birthweight. P. vivax infections during pregnancy are clearly associated with serious adverse outcomes and should be considered in prevention strategies of pregnancy-associated malaria.


Assuntos
Malária Vivax/epidemiologia , Plasmodium vivax , Complicações Parasitárias na Gravidez/epidemiologia , Adolescente , Adulto , Anemia/epidemiologia , Anemia/parasitologia , Bolívia/epidemiologia , Monitoramento Epidemiológico , Feminino , Humanos , Recém-Nascido de Baixo Peso , Recém-Nascido , Malária Vivax/parasitologia , Pessoa de Meia-Idade , Placenta/parasitologia , Gravidez , Complicações Parasitárias na Gravidez/parasitologia , Prevalência , Fatores de Risco , Adulto Jovem
5.
Cuad. Hosp. Clín ; 54(1): 27-33, 2009.
Artigo em Espanhol | LILACS | ID: lil-779272

RESUMO

Se realizó una evaluación in vivo de la eficacia de la cloroquina para el tratamiento de la malaria por Plasmodium vivax, en elsitio centinela de Palmar Chico, Municipio de Yacuiba, Provincia Gran Chaco, Departamento de Tarija al Sur de Bolivia. Fueronincluidos en el estudio 61 pacientes entre 5 y 59 años de edad que presentaban monoinfección por P. vivax. Todos los pacientesrecibieron una dosis total de cloroquina de 25 mg/Kg en 3 días (10mg/Kg el primer día; 7,5 mg/Kg el segundo y tercer días).De acuerdo al protocolo estandarizado de la OPS/OMS, todos los pacientes fueron seguidos por 28 días (controles clínicos yparasitológicos). Se completó el seguimiento de 60 pacientes, ninguno de los pacientes tuvo recurrencias de la parasitemia opresentó manifestaciones clínicas después del tercer día de tratamiento. Este estudio mostró 100% de sensibilidad de P. vivaxa la cloroquina, lo que justifica su permanencia en la política de medicamentos antimaláricos como la droga más adecuada parael tratamiento de las infecciones por P. vivax en el Sur de Bolivia.


We carried out an evaluation in vivoof the chloroquine efficacy for the treatment of malaria by Plasmodium vivax, in the sentinelsite of Palmar Chico, Municipality of Yacuiba, Province Gran Chaco, Department of Tarija to the South of Bolivia. Sixty one patientsaged between 5 and 59 years that presented monoinfection by P. vivaxwere included in the study. All patient received undersupervision a total dose of chloroquine 25mg/kg over three days (10mg/kg on the first day; 7.5 mg/kg on the second and thirddays). According the standardized protocol of the PAHO/WHO, all patients were followed-up for 28 days (clinical and parasitologicalcontrols). Sixty patients completed the follow-up, none of the patients had recurrences of parasitemia or presented clinicalmanifestations after third day of treatment. This study showed 100% of sensibility from P. vivax to chloroquine, what justifies theirpermanency in the antimalarial drug policy as the most adequate drug for the treatment of the P. vivax infections in the South of Bolivia.


Assuntos
Humanos , Criança , Adolescente , Adulto Jovem , Pessoa de Meia-Idade , Cloroquina/uso terapêutico , Malária Vivax/terapia , Plasmodium vivax/parasitologia , Antimaláricos/uso terapêutico , Bolívia , Infecções por Protozoários/parasitologia , Resultado do Tratamento
6.
Trop Med Int Health ; 9(2): 217-21, 2004 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-15040558

RESUMO

We assessed the efficacy of mefloquine monotherapy and mefloquine-artesunate (MQ-AS) combination therapy for the treatment of Plasmodium falciparum malaria at four sites in the Bolivian Amazon region. Patients with uncomplicated P. falciparum infections between 5 and 60 years of age were randomly assigned to be treated with either MQ (15 mg/kg in a single oral dose) or MQ (15 mg/kg) plus AS (4 mg/kg daily for 3 days). A total of 143 patients were enrolled and followed for 28 days. None of the 73 patients who received MQ alone or the 70 patients who received MQ-AS combination therapy had recurrences of parasitaemia during the 28-day follow-up period. Asexual parasite densities fell significantly more rapidly and the proportion of patients with gametocytes was significantly lower on days 7-28 in patients treated with MQ-AS than in those treated with MQ alone. All patients tolerated the medications well. After this study, the Bolivian Ministry of Public Health changed its treatment policy for uncomplicated P. falciparum malaria in the Amazon region to combination therapy with MQ-AS to slow or prevent the development of resistance.


Assuntos
Antimaláricos/uso terapêutico , Artemisininas/uso terapêutico , Malária Falciparum/tratamento farmacológico , Mefloquina/uso terapêutico , Sesquiterpenos/uso terapêutico , Adolescente , Adulto , Antimaláricos/efeitos adversos , Artemisininas/efeitos adversos , Artesunato , Bolívia , Criança , Pré-Escolar , Quimioterapia Combinada , Feminino , Humanos , Malária Falciparum/sangue , Masculino , Mefloquina/efeitos adversos , Pessoa de Meia-Idade , Parasitemia/tratamento farmacológico , Sesquiterpenos/efeitos adversos , Resultado do Tratamento
7.
Am J Trop Med Hyg ; 68(4): 391-7, 2003 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-12875285

RESUMO

The World Health Organization (WHO) has developed guidelines for in vivo antimalarial drug efficacy testing for Plasmodium falciparum and Plasmodium vivax in areas with low-to-moderate transmission, such as the Americas. These guidelines are used widely by ministries of health and national malaria control programs to assess the efficacy of their first-line and second-line drugs for the treatment of malaria and to provide the information necessary to update national malaria treatment policies. Following the WHO guidelines, we have conducted in vivo efficacy trials with a variety of drugs and drug combinations against P. falciparum and P. vivax at 13 sites in Peru, Bolivia, and Ecuador. Based on these experiences, we have identified several modifications that we believe should be made in the WHO recommendations to make them more suitable to the relatively low levels of P. falciparum transmission in the Americas and to the logistic challenges of carrying out such studies in sparsely populated areas, such as the Amazon Basin. These include changes in inclusion and exclusion criteria, in enrollment and follow-up procedures, and in the measurement of study outcomes.


Assuntos
Antimaláricos/normas , Antimaláricos/uso terapêutico , Guias como Assunto/normas , Malária Falciparum/tratamento farmacológico , Malária Vivax/tratamento farmacológico , Animais , Bolívia/epidemiologia , Equador/epidemiologia , Feminino , Seguimentos , Humanos , Incidência , Malária Falciparum/epidemiologia , Malária Falciparum/parasitologia , Malária Vivax/epidemiologia , Malária Vivax/parasitologia , Parasitemia/tratamento farmacológico , Parasitemia/parasitologia , Cooperação do Paciente , Seleção de Pacientes , Peru/epidemiologia , Gravidez , Recidiva , Tamanho da Amostra , Fatores de Tempo , Resultado do Tratamento , Organização Mundial da Saúde
13.
Rev. colomb. obstet. ginecol ; 52(4): 367-370, nov. 2001.
Artigo em Espanhol | LILACS | ID: lil-315809

RESUMO

La hidrolaparoscopia transvaginal fue descrita por Gordts y cols en 1998 como una herramienta para el diagnóstico de la mujer infértil; sin embargo, su difusión e implentación como método de rutina ha sido un poco lenta, pues aún existen dudas acerca de la seguridad y la eficacia de la técnica en el diagnóstico y tratamiento de las patologías pélvicas relacionadas con los problemas de fertilidad de la mujer, pues las publicaciones a la fecha refieren hasta un 5 por ciento de complicaciones (perforación del recto, no acceso a cavidad abdominal, hematomas y sangrados vaginales). En el presente artículo presentamos una modificación al protocolo de la técnica descrita originalmente, así como la implementación de un nuevo instrumento con el cual es posible lograr un acceso seguro a la cavidad abdominal a través del fondo de saco, evitando riesgos de daños a las estructuras intraabominales y permitiendo la inspección de la pelvis para realizar la fertiloscopia o hidrolaparoscopia transvaginal


Assuntos
Feminino , Culdoscopia , Histeroscopia , Laparoscopia , Infertilidade
14.
Cochabamba; UMSS - FAC.AGRONOMIA - TESIS; 2001. 72 ; 28 cm p. ilus.
Tese em Espanhol | LIBOCS, LIBOSP | ID: biblio-1334206

RESUMO

Con la hipótesis, de que el uso de lombrices, permite acelerar los procesos de descomposición y transformación de los desechos orgánicos en un producto útil. Y con los objetivos de determinar, el efecto de diferentes poblaciones de lombrices (Lumbricus rubellus), sobre la basura urbana, y determinación de cuál la población más apropiada para descomponer con menores tiempo y costo. Se evaluaron 4 poblaciones (0, 100, 200 y 400 g de L. rubellus); utilizando el diseño completamente aleatorio con 3 repeticiones. Las variables: porcentaje de descomposición, número de lombrices y número de huevos/1 099 cm3, indican que, cualquierea de los tratamientos com lombrices, desde 100 hasta 400 g descomponen la materia orgánica en 75 días con un periodo previo de 13 días de acondicionamiento. Las conclusiones finales son: la población de 100 g de lombrices, para (0.35x0.35m) de cantero o su equivalente 980 g por m2 (1x1x0.4m) de cantero normal es la mejor; por su menor costo e igual eficiencia. Ed recomendable el uso de lombrices en la descomposición de la basura orgánica y comvertirla en humus.


Assuntos
Oligoquetos , Resíduos , Resíduos Sólidos , Solo
15.
In. Tlaxcala. Secretaria de Salud; Organización Panamericana de la Salud. Fortalecimiento de los sistemas locales de salud: jurisdiccionales y municipales. s.l, Tlaxcala. Secretaria de Salud, 1988. p.217-243.
Monografia em Espanhol | LILACS | ID: lil-60943
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...